PGY2 Solid Organ Transplant Pharmacy Residency

at Newark Beth Israel Medical Center

Purpose

The PGY2 Solid Organ Transplant Residency Program builds upon Doctor of Pharmacy (PharmD) education and PGY1 pharmacy residency training to develop pharmacist practitioners with knowledge, skills, and abilities as defined in the educational competency areas, goals, and objectives for advanced practice areas. Residents who successfully complete the PGY2 Solid Organ Transplant Residency Program are prepared for advanced patient care or other specialized positions, and board certification in the advanced practice area.

Program Goals

Newark Beth Israel is home to one of the nation’s 10 largest heart transplant centers, RWJBarnabas Health’s Heart Failure Treatment and Transplant Program and New Jersey’s only Advanced Lung Disease and Transplant Program.

The RWJBH PGY2 Solid Organ Transplant Pharmacy Residency Program at Newark Beth Israel Medical Center is a 12-month educational and training experience designed to develop expert knowledge, skills, and leadership in the practice of transplant pharmacy. Residents will gain well-rounded experiences and provide direct patient care in a variety of solid organ transplants, including inpatient and outpatient services. Additionally, residents will be involved in various educational, administrative, and research projects and presentations. Upon completion of the residency program, residents will be prepared to practice at the top of their license as a board-certified solid organ transplant clinical pharmacist.

Application Deadline: January 6, 2027

Residency Start Date: July 6, 2027

Number of Positions: 1